Storage, Stability, and Reconstitution of Tesamorelin for Controlled Laboratory Research
Storage, Stability, and Reconstitution of Tesamorelin for Controlled Laboratory Research
Disclaimer: Tesamorelin is sold by Palmetto Peptides exclusively for laboratory and preclinical research use. It is not intended for human or veterinary use, and nothing in this article constitutes medical advice. All handling must comply with applicable institutional biosafety and regulatory requirements.
Why Proper Handling Matters: The Quick Answer
Tesamorelin is a relatively stable synthetic peptide compared to native GHRH, but its bioactivity in laboratory assays depends directly on how it is stored and prepared. Improper storage can lead to aggregation, oxidation of sensitive residues, or hydrolysis of peptide bonds — all of which degrade biological activity without necessarily producing visible signs of degradation. Following established protocols is not optional for researchers expecting reproducible results.
Understanding Tesamorelin's Stability Profile
Before getting into specific protocols, it helps to understand the chemical features that govern tesamorelin's stability. This context makes the rationale behind each handling recommendation clear rather than arbitrary.
The Methionine Residue
Tesamorelin contains a methionine residue at position 27 of the GHRH(1-44) sequence. Methionine's thioether side chain is susceptible to oxidation — particularly in the presence of dissolved oxygen, oxidizing agents, or peroxides. Methionine oxidation converts the thioether to a sulfoxide or sulfone, altering the local peptide conformation and potentially reducing GHRH-R binding affinity. This is one of the primary mechanisms of tesamorelin degradation in solution and drives several of the handling recommendations below.
No Disulfide Bonds
Tesamorelin does not contain cysteine residues, so disulfide bond formation and scrambling are not stability concerns. This simplifies handling compared to peptides like IGF-1 that contain multiple cysteines.
Peptide Bond Hydrolysis
Like all peptides, tesamorelin is susceptible to hydrolysis of its backbone peptide bonds. This process is accelerated at extreme pH values (below 3 or above 8), at elevated temperatures, and with prolonged storage in aqueous solution. Maintaining near-neutral to slightly acidic pH in solution and limiting time in the reconstituted state minimizes this risk.
Aggregation
At high concentrations or in the presence of significant agitation, tesamorelin can aggregate — forming non-covalent multimeric assemblies that reduce monomeric peptide concentration and may alter biological activity. Gentle handling, appropriate concentration ranges, and controlled storage conditions reduce aggregation risk.
Lyophilized Storage: The Starting Point
Tesamorelin is supplied by Palmetto Peptides as a lyophilized (freeze-dried) powder. This form is inherently more stable than any solution form because:
- Removal of water eliminates hydrolysis and dramatically slows oxidation
- Reduced molecular mobility slows degradation reactions
- The compact, dry matrix protects peptide structure
Storage Temperature for Lyophilized Tesamorelin
| Storage Duration | Recommended Temperature |
|---|---|
| Short-term (up to 3 months) | -20°C |
| Long-term (3 months to 1+ year) | -80°C |
| Transit (brief) | Refrigerated (2-8°C) with desiccant |
Keep vials sealed until use. Once a vial is opened and reconstituted, the lyophilized form is gone — all remaining quantity transitions to solution stability considerations.
Protecting from Moisture and Light
Lyophilized peptides are hygroscopic — they readily absorb ambient moisture, which initiates degradation. Store vials in a desiccant-containing container if possible, and avoid opening vials in humid conditions. While tesamorelin is not acutely photosensitive, minimizing UV exposure through amber vial storage or dark containers is standard practice for research peptides.
Reconstitution Protocol for Laboratory Use
Reconstitution is the process of adding a solvent to the lyophilized peptide powder to prepare a solution for experimental use. Doing this correctly is critical for achieving full dissolution, maintaining peptide integrity, and establishing an accurate working concentration.
Step 1: Bring the Vial to Room Temperature
Before opening or adding solvent, allow the sealed vial to equilibrate to room temperature. This prevents condensation from forming inside the vial when it is opened, which could introduce unwanted moisture and dilute the peptide unevenly.
Step 2: Select the Appropriate Reconstitution Solvent
Tesamorelin solubility and stability are best maintained in slightly acidic aqueous conditions. Appropriate solvents include:
- Sterile water for injection (USP-grade): Suitable for most laboratory applications; pH will be approximately neutral
- 0.1% to 1% acetic acid in sterile water: Preferred for maximizing solubility and minimizing methionine oxidation risk; slight acidity suppresses oxidation kinetics
- Phosphate-buffered saline (PBS), pH 7.0-7.4: Acceptable for some applications but less ideal due to slightly higher pH and potential ion interactions
Solvents to avoid: - DMSO: Can oxidize methionine over time; not recommended - Ethanol or other organic solvents: Not appropriate for this water-soluble peptide - Strongly alkaline solutions (pH > 8): Accelerates peptide bond hydrolysis
Step 3: Add Solvent Slowly and Gently
Use a sterile syringe to introduce the reconstitution solvent slowly and against the vial wall — not directly onto the lyophilized cake. Direct impingement of liquid onto the powder can cause foaming and mechanical disruption. Allow the solvent to wet the powder from the sides and bottom of the vial.
Step 4: Gently Swirl — Do Not Vortex
After adding the solvent, gently swirl or roll the vial between your palms to encourage dissolution. Do not vortex the vial. Vigorous mechanical agitation promotes peptide aggregation and can introduce air bubbles that accelerate oxidation at air-liquid interfaces.
Step 5: Inspect for Complete Dissolution
Tesamorelin should dissolve to produce a clear, colorless to slightly yellow solution. Cloudiness or visible particulates suggest incomplete dissolution or aggregation. If the solution remains cloudy, gentle warming to 25-30°C (not exceeding 37°C) may help, but any cloudiness that persists after this suggests degradation or an incompatible solvent.
Step 6: Establish Working Concentration
Calculate the volume of solvent needed to achieve the desired working concentration based on the stated peptide mass in the vial. Common working concentrations for laboratory assays range from 0.1 to 1.0 mg/mL, though this will vary by experimental design. Document the calculated concentration, batch number, and reconstitution date for traceability.
Post-Reconstitution Stability and Storage
Once reconstituted, tesamorelin transitions to the less stable solution form. Storage conditions and use timelines become more critical.
Short-Term Use (Within 24-72 Hours)
If the reconstituted peptide will be used within 24-72 hours, store the vial at 2-8°C (standard laboratory refrigerator temperature) in a sealed container protected from light. Minimize the time the vial is at room temperature between uses.
Longer-Term Storage of Reconstituted Stock
For experiments that will be conducted over a longer period, the preferred approach is:
- Reconstitute the full vial contents
- Immediately aliquot into single-use volumes in labeled, sealed cryovials
- Freeze aliquots at -20°C (acceptable) or -80°C (preferred)
- Thaw individual aliquots as needed; never refreeze a thawed aliquot
This aliquoting strategy eliminates repeated freeze-thaw cycles and significantly extends the effective usable lifetime of the peptide.
Freeze-Thaw Cycle Limits
Each freeze-thaw cycle degrades tesamorelin through a combination of ice crystal disruption, oxidation during thawing, and concentration at phase boundaries. Research labs should treat each thawed aliquot as single-use.
Concentration Calculations: A Practical Reference
For researchers preparing tesamorelin solutions, the following reference helps with concentration calculations.
If your vial contains 2 mg of tesamorelin: - Adding 2 mL of solvent gives a 1 mg/mL (approximately 0.19 mM) stock solution - Adding 4 mL gives 0.5 mg/mL stock solution - Adding 10 mL gives 0.2 mg/mL stock solution
Remember that these are approximate concentrations based on stated vial mass. Certificate of analysis purity values should be used to refine actual molar concentrations for assays requiring precise molarity.
Common Handling Errors and How to Avoid Them
| Common Error | Consequence | Prevention |
|---|---|---|
| Vortex mixing after reconstitution | Aggregation, air bubble formation | Gentle swirl only |
| Using DMSO as reconstitution solvent | Methionine oxidation | Use aqueous acidic solvent |
| Repeated freeze-thaw of reconstituted stock | Structural degradation | Aliquot before first freeze |
| Storing lyophilized vials at -4°C | Accelerated degradation vs. -20°C | Always use -20°C or colder |
| Reconstituting in strongly alkaline buffer | Peptide bond hydrolysis | Target pH 4.0-7.0 |
| Leaving reconstituted solution at RT for hours | Oxidation, hydrolysis | Refrigerate immediately after use |
Connecting Storage to Research Quality
Researchers who invest in high-purity tesamorelin from a reputable supplier and then handle it improperly can end up conducting assays with a degraded compound — getting unpredictable results that may incorrectly reflect on the peptide's biological properties rather than on handling errors. Traceability (recording batch numbers, reconstitution dates, solvent used, and storage conditions) allows researchers to identify handling-related variables if unexpected results arise.
For related protocols, see our articles on Tesamorelin Peptide Shelf Life and Long-Term Stability in Research Lab Conditions and Analytical Testing Methods for High-Purity Tesamorelin in Scientific Research Settings.
For research-grade tesamorelin with documented purity, visit the Palmetto Peptides Tesamorelin product page. For related GH axis research peptides, see our CJC-1295, Sermorelin, and Ipamorelin product pages.
Summary
Tesamorelin arrives as a lyophilized powder and should be stored at -20°C to -80°C until use. Reconstitution in sterile water or dilute acetic acid solution using gentle swirling — not vortexing — protects peptide integrity. Reconstituted solutions are best used within 24-72 hours or aliquoted and stored at -20°C or colder in single-use volumes. The methionine at position 27 is the primary oxidation-sensitive residue, driving the preference for slightly acidic aqueous solvents and avoidance of DMSO and other oxidizing conditions. Freeze-thaw cycling should be minimized by aliquoting before the first freeze.
Frequently Asked Questions
Q: What are the recommended storage conditions for lyophilized tesamorelin? Lyophilized tesamorelin should be stored at -20°C or colder, protected from light and moisture. For long-term storage exceeding several months, -80°C is preferable.
Q: What solvent should be used to reconstitute tesamorelin for laboratory use? Tesamorelin is typically reconstituted in sterile water or a dilute acetic acid solution (0.1% to 1% acetic acid in sterile water). Slightly acidic conditions improve solubility and minimize methionine oxidation.
Q: How long is reconstituted tesamorelin stable in laboratory conditions? Reconstituted tesamorelin is most stable when stored at 2-8°C and used within 24-72 hours. For longer storage, aliquot into single-use volumes and freeze at -20°C.
Q: Why should DMSO not be used to reconstitute tesamorelin? DMSO can promote oxidation of the methionine residue at position 27 of tesamorelin, altering its structure and potentially reducing receptor binding activity in laboratory assays.
Q: Can tesamorelin be refrozen after reconstitution? Tesamorelin can be refrozen, but each freeze-thaw cycle increases the risk of peptide aggregation and structural degradation. Best practice is to aliquot into single-use volumes before freezing.
Related Research
- Palmetto Peptides Guide to the Research Peptide Tesamorelin — Full tesamorelin overview including a storage and reconstitution protocol summary for new researchers.
- Tesamorelin Shelf Life and Long-Term Stability for Multi-Week Preclinical Studies — Extended shelf life data, degradation mechanism detail, and multi-month study planning guidance.
- Evaluating Purity and Quality of Tesamorelin Research Peptides — How post-storage analytical re-verification connects to handling protocols.
- Analytical Testing Methods for High-Purity Tesamorelin in Scientific Research Settings — Methods to confirm compound integrity after reconstitution, including the +16 Da oxidation signature detectable by MS.
- Buying Tesamorelin for Research: Supplier Selection, Purity Standards, and Sourcing Best Practices — What to confirm about cold-chain handling and lyophilized format before sourcing.
- Tesamorelin Chemical Structure and Synthesis: What Researchers Need to Know — The molecular basis for Met-27 oxidation vulnerability and the role of counterions in net peptide content.
Products Referenced: - Tesamorelin — Palmetto Peptides - CJC-1295 — Palmetto Peptides - Sermorelin — Palmetto Peptides - Ipamorelin — Palmetto Peptides
References
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575.
- Jorgensen L, Hostrup S, Moeller EH, Grohganz H. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. Expert Opin Drug Deliv. 2009;6(11):1219-1230.
- Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-377.
- Lasko CM, Baker DL, Bhatt DL, et al. Characterization of tesamorelin (TH9507), a stabilized analogue of human growth hormone-releasing factor. J Endocrinol. 2008;197(3):491-499.
- Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003;20(9):1325-1336.
- Schüle S, Schulz-Fademrecht T, Garidel P, Bechtold-Peters K, Friess W. Stabilization of IgG1 in spray-dried powders for inhalation. Eur J Pharm Biopharm. 2008;69(3):793-807.
Palmetto Peptides Research Team
This article is intended for informational and educational purposes for licensed researchers only. Tesamorelin is sold exclusively for laboratory research and is not approved for human or veterinary use. Always comply with institutional protocols when handling research peptides.
Part of the Tesamorelin Research Guide — Palmetto Peptides comprehensive research resource.